Proclara Biosciences (formerly NeuroPhage Pharmaceuticals) was founded in 2006 to develop novel methods for treating neurodegenerative diseases.

Its platform General Amyloid Interaction Motif (GAIM) technology recognize and target multiple misfolded proteins, enabling clinicians to make a transformative impact on the lives of patients. Lead candidate NPT088 combines a GAIM fusion protein with a immunoglobulin to target amyloid proteins. It has currently completed preclinical trials, and the company is investigating its therapeutic value in Alzheimer's, Parkinson's and other neurodegenerative diseases.